Confirm Rx

2017: Beginning of sales

In May, 2017 Abbott Laboratories about the beginning of practical use as the company claims, the first-ever implanted cardiomonitor capable to be synchronized with the smartphone. The product which received the name Confirm Rx was developed by St. Jude Medical company which Abbott purchased at the beginning of 2017.

The compact device of the size of the USB drive is implanted hypodermically into the area of heart for the purpose of continuous diagnostics of a warm rhythm. The device is intended for patients with clinical syndromes or the increased risk of cardiac arrhythmias (including fibrillation of auricles).

The implanted Confirm Rx cardiomonitor

The implanted cardiomonitor reveals and writes all episodes of violation of a rhythm of heart. Information is transferred through a wireless channel to mobile application of myMerlin thanks to what doctors can monitor remotely a status of patients and precisely diagnose deviations in work of heart. The interface of the program is translated into 35 languages, including into Russian.

Patients can independently write data on the health in the smartphone: for example, to specify weakness, tachycardia and other information which can be useful to the doctor for diagnosis and purpose of treatment.

The producer claims that, in addition to contact with the smartphone, the new cardiomonitor differs from the competing products in the smallest thickness. The device offers intuitive programming by means of one button and remote monitoring through a single network of Merlin.net Patient Care Network.

In May, 2017 Confirm Rx got approval for sale in Europe then it appeared in 10 countries of the region at once. In the second quarter the product will be available in all European Union. By May, 2017 it is under consideration in the American Food and Drug Administration (FDA). The certificate of FDA is necessary for distribution of the medical equipment to the USA.

According to forecasts of Abbott, in 2017 the volume of the world market of cardiomonitors will be $800 million. Annual growth rates of sales of this equipment estimate at the level of $100 million^[1] at the companies]

Notes